Studies related to Breast Tenderness and Vitex agnus castus

Evaluating Therapeutic Effect In Symptoms Of Moderate-to-severe Premenstrual Syndrome With Vitex Agnus Castus (BNO 1095) In Chinese Women

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 64
Gender Female
Age Range 18-29, 30-44
Body Types Average
Notes for this study:
4mg of BNO 1095 (10:1 concentrated ethanolic extract of the plant) daily appears to reduce a variety of symptoms in Chinese women suffering moderate to severe PMS symptoms when taken daily.

Therapeutic Effect Of Vitex Agnus Castus In Patients With Premenstrual Syndrome

Effect Decrease
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 128
Gender Female
Age Range 18-29, 30-44
Body Types Overweight, Average
Notes for this study:
4.5mg (40 drops) of Vitex Agnus taken 6 days prior to menstruation and continued for 3 months was associated with improved symptoms of PMS relative to placebo.

Dose-dependent Efficacy Of The Vitex Agnus Castus Extract Ze 440 In Patients Suffering From Premenstrual Syndrome

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 146
Gender Female
Age Range 18-29, 30-44
Body Types Average
Notes for this study:
Relative to placebo, symptoms of PMS were significantly reduced associated with all tested doses of Ze 110 (8, 20, 30mg) and although both higher doses outperfomed 8mg, there were no significant differences between 20mg and 30mg. Assessed by VAS

Efficacy And Safety Of Vitex Agnus-castus Extract For Treatment Of Premenstrual Syndrome In Japanese Patients: A Prospective, Open-label Study

Effect Decrease
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 67
Gender Female
Age Range 18-29, 30-44
Body Types Average
Notes for this study:
Supplementation of a vitex agnus castus supplement (Prefemin; 20mg of a 60% water-ethanolic extract; 6-12:1 concentrated) daily for three menstrual cycles in an open-label study noted that all symptoms of PMS decreased when measured at the first and third cycles compared to baseline.

Medication appears to be well tolerated aside from one acute reaction which appeared to be allergic dermatitis.
Funding issues for this study:
Some potential conflicts of interest with authors and the manufacturer of the supplement